Serum matrilysin correlates with poor survival independently of KRAS and BRAF status in refractory advanced colorectal cancer patients treated with irinotecan plus cetuximab. [electronic resource]
Producer: 20110411Description: 417-24 p. digitalISSN:- 1423-0380
- Adenocarcinoma -- blood
- Adult
- Aged
- Aged, 80 and over
- Antibodies, Monoclonal -- therapeutic use
- Antibodies, Monoclonal, Humanized
- Antineoplastic Agents -- therapeutic use
- Biomarkers, Tumor -- blood
- Camptothecin -- analogs & derivatives
- Cetuximab
- Colorectal Neoplasms -- blood
- Drug Resistance, Neoplasm
- Drug Therapy, Combination
- Female
- Humans
- Irinotecan
- Male
- Matrix Metalloproteinase 7 -- blood
- Middle Aged
- Mutation -- genetics
- Predictive Value of Tests
- Prognosis
- Proto-Oncogene Proteins -- genetics
- Proto-Oncogene Proteins B-raf -- genetics
- Proto-Oncogene Proteins p21(ras)
- Retrospective Studies
- Survival Rate
- Treatment Outcome
- ras Proteins -- genetics
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.